The Impact Investor | ESG Investing Blog

Investing for financial return is only part of the equation.

JOIN

Updated on

Our posts may contain links from our affiliate partners. This supports helps support the site as we donate 10% of all profits to sustainability organizations that align with our values. However, this does not influence our opinions or ratings. Please read our Terms and Conditions for more information.

Our Eli Lilly and Company (LLY) ESG Review

Eli Lilly and Company
$923.71
SymbolLLY
Price$923.71
52 Week High 📈$972.53
52 Week Low 📉$516.57
Earnings Per Share 💵8.13
Dividend Yield 🔁0.56

Our Take

Eli Lilly is a global pharmaceutical company that creates medicines for a wide range of serious illnesses. The company has been in operation since 1876, and today it operates in more than 143 countries around the world.
Lilly is committed to responsible business practices and strives to make a positive impact on society through its business activities. As part of this commitment, Lilly has adopted an Environmental, Social, and Governance (ESG) policy.
The company’s ESG policy sets out Lilly’s approach to managing environmental, social, and governance issues in its business. The policy covers a range of topics, including climate change, employee health and safety, human rights, responsible marketing, and supply chain management.
Lilly’s climate change strategy includes a goal to reduce greenhouse gas emissions by 25% by 2025 (from a 2015 baseline). The company has also set targets to increase the use of renewable energy and to improve energy efficiency.

What We Like

  • Lilly has a history of being a socially responsible company

  • The company is committed to environmental sustainability, with a goal to reduce its greenhouse gas emissions by 25% by 2025

  • Lilly has a strong focus on diversity and inclusion, with programs in place to support employees from underrepresented groups

What We Don't Like

  • The company's share price is down 7% over the past year

  • The company is facing several lawsuits alleging that it failed to warn patients of the risks associated with its diabetes drug and dulaglutide

Sector: Health Care
Industry: Pharmaceuticals
Website: www.lilly.com
Business Description

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer’s Institute. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

CompanyEli Lilly and Company
ExchangeNYSE
AddressLilly Corporate Center,, Indianapolis, USA
Go to top

Popular ESG Stocks

Popular ESG Stocks
StockMarketcapIndustryPriceChange %52 Week RangeChart (24H)EPSDividend Yield
NVDA
NVIDIA Corporation
NVDA
2.92TSemiconductors$119.100.03%
2.130.03%
MSFT
Microsoft Corporation
MSFT
3.20TSoftware - Infrastructure$430.590.84%
11.800.70%
BBY
Best Buy Co., Inc.
BBY
21.14BSpecialty Retail$98.450.72%
5.793.82%
ADBE
Adobe Inc.
ADBE
238.05BSoftware - Infrastructure$536.878.47%
11.810.00%
CRM
Salesforce, Inc.
CRM
243.37BSoftware - Application$254.570.47%
5.730.63%
INTU
Intuit Inc.
INTU
183.68BSoftware - Application$655.311.38%
10.420.63%
POOL
Pool Corporation
POOL
13.62BIndustrial Distribution$356.022.75%
11.891.35%
PYPL
PayPal Holdings, Inc.
PYPL
71.67BCredit Services$70.100.37%
4.120.00%
GOOGL
Alphabet Inc.
GOOGL
1.94TInternet Content & Information$157.461.79%
6.980.51%
FSLR
First Solar, Inc.
FSLR
24.49BSolar$228.793.03%
11.210.00%

FAQ

How much is Eli Lilly and Company (LLY) stock?

The current stock price of Eli Lilly and Company (LLY) is $923.71.

What is Eli Lilly and Company (LLY)'s ESG Score?

Eli Lilly and Company (LLY) has an ESG score of 59, BBB, and a as rated from Sustainalytics, ESG Enterprise, and MSCI, respectively.